Connect
MJA
MJA

COX-2 inhibitors: exemplars of the drug-safety conundrum

Mark R Nelson, Andrew M Tonkin, Flavia M Cicuttini and John J McNeil
Med J Aust 2005; 182 (6): 262-263.
Published online: 21 March 2005

Using clinical trials to assess long-term drug safety is problematic; in Australia, simple data linkage based on Medicare numbers may provide useful monitoring information

The era of pharmaceutical medicines began with the synthesis of acetylsalicylic acid (ASA) in the late 19th century. The reason for its synthesis was that natural salicylic acid was irritating to gastric mucosa, and the synthesised product less so. Subsequently, more potent non-steroidal anti-inflammatory drugs (NSAIDs) were introduced and, more recently, cyclooxygenase-2 (COX-2) inhibitors, also with a lesser risk of gastric irritation and bleeding. 1 The rapidly widespread and often prolonged use of these agents meant that even a small increase in the risk of a serious adverse event could be very significant in population health terms.

  • Mark R Nelson1
  • Andrew M Tonkin2
  • Flavia M Cicuttini3
  • John J McNeil4

  • 1 University of Tasmania, Hobart, TAS.
  • 2 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC.

Correspondence: Mark.Nelson@utas.edu.au

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.